IN8BIO, INC.
Genetically modified gamma-delta T cell immunotherapy for cancer treatment
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2018
- Latest Form D
- $20.1M, Dec 2025
- Total capital
- $51.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $51.7M
- 4 Form D · last Dec 2025
- 10 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 20 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$20.1M
- Private capital raisedForm D · SEC · 3rd filing$12.4M
- Private capital raisedForm D · SEC · 2nd filing$14.4M
- Private capital raisedForm D · SEC · 1st filing$4.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Alan S. RoemerDirectorNamed in SEC Form D filings
- Corinne R. EpperlyDirectorNamed in SEC Form D filings
- Emily R. FairbairnDirectorNamed in SEC Form D filings
- Jeremy R. GraffDirectorNamed in SEC Form D filings
- Kate R. RochlinExecutive OfficerNamed in SEC Form D filings
- Larry LambExecutive OfficerNamed in SEC Form D filings
Show all 15 people
- Lawrence R. LambExecutive OfficerNamed in SEC Form D filings
- Luba R. GreenwoodDirectorNamed in SEC Form D filings
- Melissa BeelenExecutive OfficerNamed in SEC Form D filings
- Patrick McCallExecutive OfficerNamed in SEC Form D filings
- Peter S. BrandtDirectorNamed in SEC Form D filings
- Thomas CirritoDirectorNamed in SEC Form D filings
- Travis WhitfillDirectorNamed in SEC Form D filings
- Trishna R. GoswamiExecutive OfficerNamed in SEC Form D filings
- William HoExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 20- PendingMultivalent Chlorotoxin Chimeric Antigen ReceptorsUSPTOApplication 19174283
- PendingNon-Signaling Chimeric Antigen Receptor Gamma Delta T-CellsUSPTOApplication 19295942
- PendingIPSC-Based Gamma-Delta T-Cells, Compositions and Methods of Use ThereofUSPTOApplication 18909285
Show all 20 patent records
- Multivalent Chlorotoxin Chimeric Antigen ReceptorsMar 19, 2026 · Application 19174283Pending
- Non-Signaling Chimeric Antigen Receptor Gamma Delta T-CellsJan 15, 2026 · Application 19295942Pending
- IPSC-Based Gamma-Delta T-Cells, Compositions and Methods of Use ThereofMar 27, 2025 · Application 18909285Pending
- Multivalent Chlorotoxin Chimeric Antigen ReceptorsAug 18, 2022 · Application 17580199Pending
- Multifunctional Molecules And Methods For Cancer ImmunotherapyApplication 63777097Pending
- Multifunctional Molecules And Methods For Cancer ImmunotherapyApplication 63765174Pending
- Methods Of Allogeneic Hematopoietic Stem Cell Transplantation And Cancer TreatmentApplication PCTUS2024054062Pending
- Multifunctional Molecules And Methods For Cancer ImmunotherapyApplication 63665609Pending
- Non-signaling Chimeric Antigen Receptor Gamma Delta T-cellsApplication PCTUS2024016112Pending
- Methods Of Allogeneic Hematopoietic Stem Cell Transplantation And Cancer TreatmentApplication 63607740Pending
- Non-signaling Chimeric Antigen Receptor Gamma Delta T-cellsApplication 63459910Pending
- Ipsc-based Gamma-delta T-cells, Compositions And Methods Of Use ThereofApplication PCTUS2023018127Pending
- Non-signaling Chimeric Antigen Receptor Gamma Delta T-cellsApplication 63446484Pending
- Ipsc-based Gamma-delta T-cells, Compositions And Methods Of Use ThereofApplication 63329633Pending
- Multivalent Chlorotoxin Chimeric Antigen ReceptorsApplication PCTUS2022013130Pending
- Multivalent Chlorotoxin Chimeric Antigen ReceptorsApplication 63172247Pending
- Multivalent Chlorotoxin Chimeric Antigen ReceptorsApplication 63139709Pending
- Multifunctional Molecules And Methods Of TreatmentApplication PCTUS2025035677Pending
- Multifunctional Molecules And Methods For Cancer ImmunotherapyApplication 63804107Pending
- Multifunctional Molecules And Methods For Cancer ImmunotherapyApplication 63790150Pending
Related companies, and why
- Checkpoint Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Longboard Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Alpheus MedicalSimilar federal contract value in Biotech · null in contracts
- Convergent TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Amylyx Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- CODEXIS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .